Published in

American Society of Nephrology, Clinical Journal of the American Society of Nephrology, 11(4), p. 1716-1723, 2009

DOI: 10.2215/cjn.02760409

Links

Tools

Export citation

Search in Google Scholar

Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease

Journal article published in 2009 by Mahmut Ilker Yilmaz, Juan Jesús Carrero ORCID, Alberto Ortiz, Jose Luis Martín-Ventura, Alper Sonmez, Mutlu Saglam, Halil Yaman, Mujdat Yenicesu, Jesús Egido, Luis Miguel Blanco-Colio
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background and objectives: Recently, we showed that soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels are diminished in hemodialysis patients and had additive effects with IL-6 on survival. Because sTWEAK plasma level has been associated with the presence of chronic kidney disease (CKD) and cardiovascular disease, we hypothesized that in patients with CKD, sTWEAK levels may relate to the increased prevalence of endothelial dysfunction that usually accompanies the decline of estimated GFR (eGFR).